PemPress - All Posts Archives | Page 2 of 7 | IPPF

Linda’s Still Standing (Patient Journey Series #8)

The IPPF conference was the light and guide that...

September 27, 2019Patrick Dunn

Minatallah Finds Her Role as a Dental Student (Patient Journey Series #7)

We were under the impression that dentists don’t actually...

September 19, 2019Patrick Dunn

Toby’s Luck (Patient Journey Series #6)

Having excellent care and support (and even an infusion...

September 12, 2019Patrick Dunn

Fred’s Perspective: Connecting with Other Patients (Patient Journey Series #5)

Just spending time with...

September 6, 2019Patrick Dunn

Kathleena Finds Strength as Both a Patient and a Doctor (Patient Journey Series #4)

I had never told anyone except my close family...

August 29, 2019Patrick Dunn

Mei Ling’s Story (Patient Journey Series #3)

I remember what it was like for me when...

August 22, 2019Patrick Dunn

Rudy Takes Control (Patient Journey Series #2)

Patient Journey Series, Story 2: Rudy Connects with the...

August 15, 2019Patrick Dunn

Halima’s Diagnosis (Patient Journey Series #1)

Welcome to the Patient Journey Series: Story 1, Halima's...

August 8, 2019Patrick Dunn

A Look Back at UNC Dental Day 2018

On October 12, 2018, I participated in the IPPF...

August 6, 2019Patrick Dunn

Ellen Levine Receives Harvard Medical School Dean’s Community Service Award

The IPPF is excited to announce that Ellen Levine,...

June 25, 2019Patrick Dunn

The IPPF Receives Grant from Sy Syms Foundation to Accelerate Diagnosis Times

The Sy Syms Foundation has awarded a $100,000 grant...

June 19, 2019Patrick Dunn

Rituxan Shown as Superior in Achieving Sustained PV Remission

Genentech announced this week that positive top line results...

June 13, 2019Patrick Dunn

NORD and Trio Health Publish New Book to Provide Critical Patient Insights Into the Burden of Living With and Treating Rare Diseases

As a NORD IAMRARE™ Registry Partner, the IPPF is...

June 3, 2019Patrick Dunn

Akari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous Pemphigoid

On April 23, 2019, Akari Therapeutics, Plc (Nasdaq: AKTX),...

May 23, 2019Patrick Dunn

European Commission Approves Roche’s MabThera (rituximab) for Pemphigus Vulgaris

On March 15, 2019, Roche announced that the European...

March 15, 2019Patrick Dunn

Principia Biopharma Announces Positive Data From Phase 2 Pemphigus Vulgaris Trial at 2019 American Academy of Dermatology Annual Meeting in Late-Breaking Presentation

On March 2, 2019, Principia Biopharma Inc. (Nasdaq: PRNB), a...

March 4, 2019Patrick Dunn

Principia Biopharma Announces the Acceptance of Data from Phase 2 Pemphigus Vulgaris Trial as a Late-Breaking Presentation at 2019 American Academy of Dermatology Meeting

On February 22, 2019, Principia Biopharma Inc. (Nasdaq: PRNB),...

February 25, 2019Patrick Dunn

IPPF 2018 Year in Review

2018 was an exciting year for the IPPF!

January 25, 2019Patrick Dunn

Breaking Bad: IgG4 in Autoimmunity

Our laboratory researches a rare and debilitating autoantibody-mediated disease...

January 18, 2019Patrick Dunn

Syntimmune Announces FDA Orphan Drug Designation for SYNT001 in Treatment of Pemphigus

On September 12, 2018, the U.S. Food and Drug...

January 11, 2019Patrick Dunn

X

Chinese (Simplified)